Gili Hart, PhD
Gili Hart is currently a Co-Manager at OPKO Biologics, focusing on pre-clinical and clinical development. Since 2013, Dr. Hart served as VP of pre-clinical and clinical pharmacology, and before that as a Senior Director. Dr. Hart has been leading the pre-clinical and clinical pharmacological activities since 2008. During 2005-2007, Dr. Hart was a research fellow in the Immunology Department at the Weizmann Institute, in Collaboration with Faculty of Immunobiology at Yale University’s School of Medicine. She received her PhD cum laude from the Weizmann institute of Science and also graduated summa cum laude from the Technion with a Biotechnology Engineering degree. Dr. Hart published numerous papers and patents, and in her scientific work she focused on autoimmunity diseases as well as on B and T cells migration that can directly affect inflammation and immune conditions. Dr. Hart has extensive experience in drug development from pre-clinical proof-of-concept studies up to global clinical studies initiation, with a broad and global understanding of regulatory requirements.
Oren Hershkovitz, PhD
Oren Hershkovitz is currently a Co-Manager at OPKO Biologics, leading R&D activities with a focus on development of manufacturing processes and CMC. Dr. Hershkovitz served as VP of R&D since 2013, after serving as a Senior Director, and has been leading R&D and CMC activities at OPKO Biologics since 2008. Dr. Hershkovitz holds a BA summa cum laude in Biotechnology Engineering from Ben-Gurion University. He was awarded a PhD in Immunology summa cum laude from Ben-Gurion University. Dr. Hershkovitz is the author of many scientific papers and patents, and has broad experience in process development for chemical and biological products, CMO management, and drug development, from initial proof-of-concept studies to global clinical studies.
Laura Moschcovich, PhD
Senior Director, CMC Operations
Dr. Laura Moschcovich joined OPKO Biologics (formerly Prolor Biotech) in 2007 as the Head of Downstream Development, leading the development of the purification process of MOD-4023 (CTP-growth hormone). In 2012 she became Project Manager responsible for overseeing three different projects in collaboration with different CMOs, taking the responsibility of the technology transfer of the processes developed at OPKO Biologics from development to production. Currently, she is leading the CMC activities as Senior Director, CMC Operations. Previously, Dr. Moschcovich worked at Target-In Ltd., an Israeli startup company in a partnership with the Hebrew University of Jerusalem, as Head of Downstream Development where she was responsible for the development of the purification process of an innovative product. Dr. Moschcovich completed a post-doctoral fellowship and received her PhD in Biochemistry from Tel Aviv University.
Ahuva Bar-Ilan, PhD
Director, Pre-Clinical and Clinicial Pharmacology
Ahuva Bar-Ilan joined OPKO Biologics (formely ModigeneTech and Prolor Biotech) in December 2006 as a senior scientist in the R&D department. Since 2012, she was an Associate Director at Prolor Biotech and was responsible for the development of immunogenicity and bio-analytical methods. Currently, she is a Director at OPKO’s pre-clinical department and is responsible for methods validation, toxicological and pharmacological activities. Prior to joining Modigentech, she was a senior scientist at NatSpears. Dr. Bar-Ilan completed her PhD in the Biochemistry and Microbiology department at Ben-Gurion University of the Negev, Israel.
Yifat Philip, LLB, MBA
Yifat Philip joined OPKO Biologics in 2013 as General Counsel and is leading the legal department. Yifat has been practicing law for more than 10 years, with previous experience working in leading law firms on international bio-tech transactions, as well as in the Israel Securities Authorities and the Department of Economic and Fiscal Law of the State Attorney, Israel. Yifat is a member of the Israel Bar Association and holds LLB. cum laude and BA in Economics from Haifa University, Master cum laude in Law and Economics from Erasmus University, The Netherlands in collaboration with Berkeley University, and MBA from the Technion-Israel Institute of Technology.